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Purpose: To investigate the effect of the B and T lymphocyte attenuator (BTLA; CD272) on cluster of differentiation
(CD)4+ T cell-mediated corneal immunopathology during murine herpetic stromal keratitis (HSK).
Methods: BALB/c mice were infected with the herpes simplex virus type 1 (HSV-1) KOS strain by corneal scarification.
The levels of BTLA expression in CD4+ and CD8+ T cells in murine peripheral blood were determined by flow cytometry
on days 0, 3, 7, 10, 14, and 21 after HSV-1 infection. BTLA expression in the infected cornea was detected by
immunohistochemistry. BALB/c mice were injected intraperitoneally with recombinant plasmid DNA encoding BTLA
(pBTLA), pcDNA3.1, or PBS on 0 and 7 days before infection and 7 days postinfection. The incidence and severity of
stromal disease, tear film virus titers, and the delayed-type hypersensitivity (DTH) reaction were then compared among
treated and control groups. The effects of pBTLA on CD4+ T cells that infiltrated into infected corneas and on type 1
helper T-cell (Th1) cytokines (interferon-gamma [IFN-γ]) were evaluated. The levels of glycoprotein D (gD) mRNA in
corneas were tested by real-time PCR. The eyes were examined histologically.
Results: BTLA expression increased both in the corneas of HSV-1 infected mice and in CD4+ T cells in the murine
peripheral blood. Systemic administration of pBTLA resulted in a diminished incidence and severity of corneal lesions
compared to controls. Treatment with pBTLA led to a decreased infiltration of CD4+ T cells into infected corneas, and
diminished Th1 responses in murine corneas, draining lymph nodes, and splenocytes. The pBTLA treated mice showed
an impaired DTH response two weeks after HSV-1 infection compared to control mice. No differences were noted in tear
film virus titers or gD mRNA levels in corneas among the experimental groups.
Conclusions: The results suggest that recombinant pBTLA plays a crucial role in preventing HSV-1 specific responses
in CD4+ Th1 cells in the infected corneas. Thus, BTLA, with immunosuppressive effects, may be a good candidate for
treatment of HSK.
Corneal  inflammation  resulting  from  herpes  simplex
virus type 1 (HSV-1) infection of the eye results in herpetic
stromal keratitis (HSK) that impairs vision and is a common
cause of human blindness [1]. Studies in animal models of
HSK  have  revealed  that  the  corneal  immunopathological
lesions of HSK appear to be orchestrated mainly by cluster of
differentiation(CD)4+ T cells that are primary type 1 helper T-
cell (h1) cytokine producers [2-4]. Cytokines characteristic of
Th1  cells  (interferon-gamma  [IFN-γ]  and  interleukin-2
[IL-2]) have been shown to dominate in HSK in preclinical
and clinical phases of disease [5], and HSK can be abrogated
by depletion of CD4+ T cells or by neutralization of Th1
cytokines  [6,7].  Several  studies  have  demonstrated  that
CD4+ Th1 cells require APC and co-stimulation to mediate
HSK, and that blocking the 4–1BB/4–1BB ligand and B7/
CD28  co-stimulatory  interactions  can  each  dramatically
reduce inflammation in the infected cornea and prevent HSK
[8-10].
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The B and T lymphocyte attenuator (BTLA; CD272), a
recently  discovered  co-receptor  expressed  in  T  cells,
negatively regulates cell activation by recruiting phosphatase
(SHP)-1/SHP-2,  and  shares  structural  and  functional
similarities  with  cytotoxic  T-Lymphocyte  Antigen-4
(CTLA-4) and programmed death 1(PD-1) [11]. Recently, the
interaction  partner  of  the  BTLA  herpes  entry  mediator
(HVEM)  has  been  identified  as  a  member  of  the  tumor
necrosis factor receptor (TNFR) superfamily [12]. HVEM is
predominantly  expressed  by  resting  T  cells,  monocytes,
immature dendritic cells (DC), and endothelial cells [13,14].
BTLA is constitutively expressed by naïve CD4+ and CD8+ T
cells and is further upregulated upon T cell activation [15]. It
is also present in B cells, macrophages, and bone marrow-
derived dendritic cells. Surface expression of BTLA and its
accumulation  at  the  immunological  synapse  are  tightly
regulated by T cell receptor ( TCR) and herpes entry mediator
(HVEM) stimulation to deliver efficient inhibitory signals in
the regulation of CD4+ T cell activation [16,17]. In accordance
with the role of BTLA as a negative receptor, mice lacking
the full-length form of BTLA are hyper-responsive to TCR-
mediated  activation  of  T  cells  [11].  BTLA  or  its  ligand
HVEM-deficient mice were more susceptible to immune and
inflammatory diseases and showed more severe pathological
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2071tissue  changes,  such  as  experimental  allergic
encephalomyelitis,  allergic  airway  inflammation,  and
intestinal inflammation, indicating that the BTLA pathway
plays  a  critical  role  in  immune-inflammatory  disease
[18-20].
In the present study, our aim was to analyze whether
BTLA  might  impair  development  of  HSK  after  HSV-1
infection  of  corneas  of  BALB/c  mice.  Our  findings
demonstrate that infection of BALB/c mice with HSV-1 KOS
strain  by  corneal  scarification  resulted  in  upregulation  of
BTLA expression in the infected corneas and in CD4+ T cells
from murine peripheral blood. Systemic administration of a
recombinant plasmid DNA encoding BTLA decreased the
numbers of CD4+ T cell that infiltrated into infected corneas,
reduced  Th1  response,  impaired  the  delayed-type
hypersensitivity (DTH) reaction, and abolished HSK lesion
development.  Our  results  are  discussed  in  terms  of  novel
approaches that merit testing for the control of HSK lesions.
METHODS
Mice: Female BALB/c Mice, 5 to 7 weeks old, were purchased
from the animal center of Beijing University (Beijing, China).
All mice were maintained in a specific pathogen-free facility
and were housed in micro-isolator cages containing sterilized
feed,  autoclaved  bedding,  and  water.  All  experimental
manipulations  were  undertaken  in  accordance  with  the
institutional  guidelines  for  the  care  and  use  of  laboratory
animals.
HSV-1 Virus, corneal infection, and detection of ocular virus
shedding: HSV-1 KOS strain was used for all procedures. A
plaque-purified stock was grown and assayed on VERO cells
in  Dulbecco’s  modified  Eagle’s  medium  (DMEM),
containing 5% fetal bovine serum, 100 U/ml penicillin, and
100 µg/ml streptomycin. Cells were cultured at 37 °C in a
humidified incubator containing 5% CO2. The BALB/c mice
were inoculated by the corneal route with HSV-1 strain KOS,
as  follows.  Briefly,  after  the  mouse  was  intraperitoneally
anesthetized with 0.5% pentobarbital (45 mg/kg bodyweight),
the corneal surface of the right eye was incised in a cross-
shaped pattern with a sterile with a 27-gauge needle, and a
5 µl drop containing 1×105 plaque-forming units (PFU) of
HSV-1 KOS was applied to the eye and gently massaged with
the  eyelids.  To  detect  ocular  virus  shedding  after  corneal
HSV-1 inoculation, material from eye swabs was plated onto
VERO cells, which were then monitored for cytopathic effects
48 and 96 h later.
Flow cytometry analysis of BTLA expression on CD4+ and
CD8+ T lymphocytes in murine peripheral blood after HSV-1
infection:  On  days  0,  3,  7,  10,  14,  and  21  after  corneal
inoculation  with  HSV-1,  murine  peripheral  blood  was
acquired  and  red  blood  cells  in  the  cell  suspension  were
removed using a lysing buffer (eBioscience, San Diego, CA).
Before staining, single cells were washed and resuspended in
staining buffer containing 1× PBS, 2%BSA, 10 mM EDTA,
and  0.01  M  NaN3.  Cells  were  then  blocked  with  an
unconjugated anti-CD32/CD16 monoclonal antibody (mAb)
for 15 min at 4 °C in staining buffer and stained by fluorescein
isothiocyanate  (FITC)-labeled  anti-CD3e  mAb,
allophycocyanin  (APC)-labeled  anti-CD4  mAb  or  APC-
labeled  anti-CD8  mAb.  Cells  were  then  fixed  and
permeabilized  using  Cytofix/Cytoperm  solution
(eBiosciences) for 30 min, followed by washing with perm
washing  solution.  Intracellular  staining  was  done  with
phycoerythrin (PE)-labeled anti-mouse BTLA/CD272 mAb
or PE-labeled mouse IgG1 isotype control for 30 min. All
antibodies were purchased from eBiosciences Inc. Cells were
incubated for 30 min on ice. After staining, the cells were
washed twice with staining buffer, and samples were acquired
on a FACSCalibur (BD Bioscience, San Jose, CA). Gates
were set based on staining with the appropriate isotype control
antibodies.  The  data  were  analyzed  using  the  CellQuest
software (BD Bioscience).
Immunohistochemical  detection  of  BTLA  expression  in
murine corneas after HSV-1 infection: Enucleated eyes were
collected at various time points post infection, fixed in 10%
buffered neutral formalin, and embedded in paraffin. Sagittal
sections 5 μm in thickness were then cut, deparaffinized, and
rehydrated. Endogenous peroxidase activity was blocked by
addition of 0.3% hydrogen peroxidase in methanol. Slides
were boiled in a target retrieval solution buffer at high pressure
for 2 min and then placed at room temperature (25 °C) for 20
min. The sections were then treated with normal goat serum
and  incubated  overnight  with  rabbit  anti-BTLA  antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 at 4 °C.
A biotinylated secondary antibody against rabbit IgG and an
avidin-biotinylated  peroxidase  complex  (Santa  Cruz
Biotechnology) were then used with 3,3′-diaminobenzidine
(DAB)  as  a  peroxidase  substrate.  Sections  were
counterstained  with  hematoxylin.  Negative  controls  were
performed by omitting the primary antibody.
Plasmid  pBTLA  preparation:  A  0.54  kb  XbaI–HindIII
fragment extracellular region of BTLA was PCR amplified
using primers F: 5′-CAG TCT AGA GCC ACC ATG AAG
ACA GTG CCT GCC ATG C-3′ (with XbaI site and initial
code) and R: 5′-GTC AAG CTT TCA GCC TGG CCT CTC
TTC CAT GGT G-3′ (with HindIII site and initial code) with
a  commercial  clone  A630002H24  (Shanghai  GeneChem
company,  Shanghai,  China)  as  a  template.  The  PCR
amplification  reaction  mixture  (50  μl)  consisted  of  dNTP
(10 μmol/l; 1 μl), 10× advantage DNA polymerase2 buffer
(5 μl), upstream and downstream primer, 1 μl each, DNA
polymerase (1 μl), template DNA (1 μl), ddH2O (40 μl).
Amplification was performed at 94 °C for 5 min, then 35
cycles at 94 °C for 30 s, at 55 °C for 30 s and at 72 °C for 2
min, followed by 10 min at 72 °C. The product was analyzed
and purified by 1.0% agarose gel electrophoresis. The PCR
amplified DNA fragments was inserted into pcDNA3.1(-)
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create the expression vector pcDNA-BTLA (named pBTLA).
Briefly, The pcDNA3.1(-) plasmid was obtained and purified
according to the manufacturer’s instructions. The recycled
plasmid  segment  and  purified  BTLA  gene  segment  were
recleaved with XbaI and HindIII respectively and purified by
hyaline. The 10 μl connection system was obtained with the
BTLA  gene  and  pcDNA3.1  (BTLA:pcDNA3.1=1:1):
pcDNA3.1 segment (4 μl), BTLA cDNA segment (4 μl), T4
DNA ligase (1 μl), 10× T4 DNA ligase buffer (1 μl), at 16 °C
overnight.  The  recombinant  was  transformed  into  E.  coli
DH5a by the CaCl2 method and transformants were selected
by agar plate containing aminopenicillin and identified by
restriction  enzyme  digestion.  Ten  anti-aminopenicillin
bacterial clones were chosen and shaken to amplify and distill
the reconstruction plasmid, which was identified by cleaving
with individual (XbaI or HindIII) and both (XbaI and HindIII)
restriction enzymes. The sequence of the inserted fragment
was confirmed by DNA sequencing (TaKaRa Biotechnology,
Dalian, China).
The  recombinant  pBTLA  was  transfected  into  the
HEK293  cell  line  (the  Institute  of  Genetics  of  Fudan
University, Shanghai, China) to express the target protein
BTLA, which was detected by indirect immunofluorescence
and  western  blotting.  HEK293  cells  were  cultured  in
minimum essential medium (MEM) supplemented with MEM
nonessential amino acids (Gibco, Grand Island, NY), 10%
FBS, 110 µg/ml sodium pyruvate, and antibiotics (100 U/ml
penicillin,  100  µg/ml  streptomycin  and  2.5  μg/ml  M-
Plasmocin). A total of 5×105 cells were seeded into each well
of a six-well plate. On the third day (when the cells had
reached  80%–90%  confluence),  the  culture  medium  was
aspirated,  and  the  cell  monolayer  was  washed  with  pre-
warmed  sterile  PBS.  Cells  were  transfected  with  the
recombinant pBTLA or the empty vector pcDNA3.1 using
Lipofectamine  2000  reagent  (Invitrogen)  according  to  the
manufacturer's  instructions.  Four  micrograms  of  plasmid
DNA (in 10 µl ddH2O) was mixed with 250 µl of serum-free
medium (SFM) and incubated for 20 min at room temperature
(25 °C) with a mixture of 10 µl Lipofectamine 2000 and 250
SFM  and  the  resulting  complex  mixture  was  added  to  a
monolayer of pre-confluent cells seeded in a six-well plate.
Forty-eight hours after transfection, the cells were fixed with
100% acetone at –20 °C for 15 min and BTLA expression was
detected using the indirect immunofluorescence assay, with a
monoclonal antibody against the BTLA protein and a FITC-
labeled rabbit-anti-mouse IgG (Sigma, St. Louis, MO).
For  western  blot  analysis,  at  24,  48,  and  72  h  after
transfection, the transfected cells were washed twice with PBS
(pH 7.4) and boiled for 10 min in lysis buffer (20 mM Tris–
HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate,  0.1%  sodium  dodecyl  sulfate).  Cell  lysates
were analyzed by 12% sodium dodecyl sulfate PAGE (SDS–
PAGE) and transferred onto nitrocellulose membrane, which
was  blocked  by  5%  skim  milk.  Primary  antibodies,  anti-
BTLA protein mAb, and a HRP-labeled rabbit-anti-mouse
IgG (1:3,000; Sigma) were diluted in washing buffer (120 mM
NaCl, 10 mM Tris, pH 7.4, 0.1% Tween-20) and incubated
for 1 h or 30 min at room temperature. After three PBS washes
and one additional wash with PBS without Tween-20, proteins
bound to the filter were scanned using an Odyssey infrared
imaging system at 680- and 800-nm wavelengths.
Plasmid pBTLA administration: The plasmids were purified
and dissolved in DNase-free sterile water to concentration of
1 µg/µl. Mice were administrated intraperitoneally (i.p.) on
days, −7, 0, and 7 with 100 µg of pBTLA or 100 µg of control
plasmid  containing  pcDNA3.1,  or  100  µl  of  phosphate
buffered saline (PBS). Each group included fifteen animals.
On day 0, the mice were scarified lightly on their cornea with
a 27-gauge needle and infected with a 5 µl drop containing
1×105 PFU of HSV-1 strain KOS.
Virus titration: Swabs of the corneal surface were collected
from day 0 to 7 after corneal inoculation. The swabs were put
into sterile tubes containing 1 ml serum-free DMEM with 100
U/ml penicillin and 100 µg/ml streptomycin, and were stored
at  −80  °C.  For  detection  and  quantification  of  virus,  the
samples were thawed and swirled gently to distribute the
sample. Individual subsamples (200 µl of each sample) were
diluted further, and viral titers were determined by standard
plaque  assays  [21].  Briefly,  monolayer  VERO  cells  were
cultured  in  12  wells  multiwell  plates  and  washed  with
Dulbecco's phosphate-buffered saline. Aliquots (200 µl) of
virus dilutions were then added to wells. After incubation for
1 h at 37 °C, maintenance medium (DMEM containing 5%
fetal  bovine  serum,  100  U/ml  penicillin  and  100  µg/ml
streptomycin) was added, and the infected monolayers were
incubated for additional 36 to 48 h to allow the formation of
discrete, well formed plaques that could be counted. The cells
were fixed and stained with 1% crystal violet dissolved in a
10%  formalin  solution,  and  the  number  of  microscopic
plaques was counted under a microscope.
Clinical observations: The eyes were examined on different
days after infection for the development of clinical lesions by
slit-lamp biomicroscopy, and the clinical severity of stromal
keratitis  of  individually  scored  mice  was  recorded.  The
stromal keratitis was graded on a scale of 0 to 4+ for corneal
opacity, corneal neovascularization, edema, and infiltration:
0, not present; 1+, less than 25%; 2+, between 25% and 50%;
3+, between 50% and 75%; and 4+, between 75% and 100%
[22].
Delayed-type  hypersensitivity  (DTH)  response:  DTH
responses were measured in uninfected (naïve) and infected
mice, including treated and control groups, on day 13 after
HSV-1  infection.  Briefly,  1×105  PFU  of  UV-inactivated
HSV-1 KOS in 30 µl of DMEM was injected into the right
rear footpad of each mouse. The left rear footpad was injected
with the same amount of virus-free tissue culture medium.
Molecular Vision 2010; 16:2071-2083 <http://www.molvis.org/molvis/v16/a223> © 2010 Molecular Vision
2073Footpad  swelling  was  measured  with  a  micrometer
immediately before and 24 h after injection. HSV-specific
footpad  swelling  was  determined  by  the  formula:  [right
footpad  swelling  at  24  h-right  footpad  swelling  before
injection]-[left footpad swelling at 24 h-left footpad swelling
before injection] [23].
Isolation  of  infiltrating  cells  in  the  corneal  stroma  and
draining lymph nodes (DLNs) and flow cytometry: Single-cell
suspensions were prepared from corneas and cervical DLNs
on day 14 postinfection. For flow cytometry measurement of
the infiltrating cells of the cornea, six corneas per group were
collected at the indicated time points by dissecting the corneal
buttons above the limbus with a scalpel. The pooled corneas
were incubated with 60 U/ml Liberase (Roche Diagnostics
Inc., Indianapolis, IN) for 60 min at 37 °C in a humidified
atmosphere of 5% CO2. After incubation, the corneas were
disrupted by grinding with a syringe plunger on a stainless
steel mesh and a single-cell suspension was made in RPMI
1640 medium with 10% FBS. Cells were counted by trypan
blue  exclusion  for  high  viability.  Next,  the  single-cell
suspensions obtained from corneal or lymphoid samples were
stained for flow cytometry. Before staining, cells were washed
and  resuspended  in  staining  buffer  containing  1×PBS,
2%BSA, 10 mM EDTA, and 0.01 NaN3. Cells were then
blocked with an unconjugated anti-CD32/CD16 mAb for 15
min at 4 °C in staining buffer and stained by fluorescein
isothiocyanate  (FITC)-labeled  anti-CD3e  mAb,
allophycocyanin (APC)-labeled anti-CD4 mAb. Next, cells
were  fixed  and  permeabilized  using  Cytofix/Cytoperm
solution (eBiosciences) for 30 min, followed by washing with
perm washing solution. Intracellular staining was done with
phycoerythrin (PE)-labeled anti-mouse IFN-γ mAb for 30
min.  PE  rat  IgG1  was  isotype  control  for  anti-IFN-γ
antibodies. All antibodies were purchased from eBiosciences
Inc. Cells were incubated for 30 min on ice. After staining,
the cells were washed twice with staining buffer, and samples
were acquired on a FACSCalibur (BD Bioscience). Gates
were set based on staining with the appropriate isotype control
antibodies.  The  data  were  analyzed  using  the  CellQuest
software (BD Bioscience).
IFN-γ assay by enzyme-linked immunosorbent assay (ELISA):
On day 14 postinfection, splenocytes were harvested from the
mice from the different groups using Ficoll-Hypaque density
gradient centrifugation. Cells were resuspended at a density
of  1×106  cells/ml  in  RPMI  1640  medium  containing  L-
glutamine (2 mM), penicillin/streptomycin (100 U/ml), and
10% fetal calf serum. Cells were cultured in 96-well plates
with  UV-inactivated  HSV-1  strain  KOS  (Multiplicity  Of
Infection=1.5  before  UV  inactivation).  Con  A-stimulated
(5  µg/106  cells/ml)  and  unstimulated  cells  were  used  as
positive  and  negative  controls,  respectively.  Plates  were
incubated  at  37  °C  for  72  h.  The  supernatant  fluid  was
collected and stored at −80 °C until use. These supernatants
were  screened  for  the  presence  of  IFN-γ  by  an  ELISA
development  kit  (R&D  Systems,  Minneapolis,  MN)
according to the manufacturer's instructions, with a detection
limit of 5 pg/ml for IFN-γ.
Real-time  quantitative  PCR  analysis:  Total  RNA  was
obtained (RNeasy Mini kit; Qiagen Co, Hilden, Germany)
from infected corneas in different treatment groups at 72 h
after HSV-1 infection and purified (on-column RNase-free
DNase kit; Qiagen Co). RNA (1 µg) was reverse transcribed
with  10  ng/ml  oligo(dT)  and  SuperScriptTM  III  reverse
transcriptase  (Invitrogen)  following  the  manufacturer’s
protocol. Amplification was performed at 65 °C for 1 min, at
30~65 °C for 30 min, at 60 °C for 30 min, at 98 °C for 5 min,
then at 5 °C for 5 min. The cDNA obtained was used as a
template for real-time quantitative PCR. The specific primers
used were murine gD forward (5′-GGC GAA GCT CAC TAC
TCA C-3′) and reverse (5′-GCG TCC ATA GCG TCC T-3′).
Reactions were set up with cDNA corresponding to 100 ng
total RNA, primers (0.4 µmol) and 10 μl SYBR green PCR
master mix (TaKaRa Co, Shiga, Japan) made to a total volume
of 20 µl with nuclease-free dH2O. The iQ5 real-time PCR
detection system (Bio-Rad, Foster, CA) was used to determine
the levels of SYBR green fluorescence 45 cycles. Samples
were degeneration for 10 min at 95 °C, anneal at 57 °C for 20
s, with extension of the primer product at 72 °C for 15 s, 45
cycles then a final 72 °C step for 20 s that removes background
fluorescence from primer-dimers. A melt curve analysis was
produced at the end of the cycling to ensure the specificity of
PCR  product  amplification  and  associated  SYBR  green
fluorescence. Initially, mRNA levels were normalized to the
GAPDH  mRNA  levels.  The  gD  expression  relative  to
GAPDH was analyzed by the 2–ΔΔCT method [24]. A relative
change in expression of twofold was set as a threshold for
determining whether differential expression of a gene had
occurred. The p values associated with the fold-change in
expression  were  calculated  using  a  one-way  ANOVA
(ANOVA) on the real-time PCR Ct values among different
groups.
Histopathology:  Animals  were  euthanized  on  day  14
postinfection.  The  eyes  were  removed  and  fixed  in  4%
formaldehyde, dehydrated, embedded in paraffin, and cut into
5-µm sections. The sections were stained with hematoxylin
and  eosin  (HE)  according  to  a  standard  protocol,  and
examined by light microscopy (Olympus, Tokyo, Japan).
Statistical analysis: All experiments were performed twice.
Mean±standard deviation (SD) values were calculated. A one-
way  ANOVA  (ANOVA)  was  used  to  determine  the
differences among groups with respect to the numbers of
CD4+ and CD4+ IFN-γ+ T cells, cytokine assay, plaque assays,
DTH, gD mRNA levels, clinical findings, and followed by a
Fisher’s LSD test. A χ2 test was used to evaluate the incidence
of disease. A p<0.05 was regarded as a significant difference
among groups.
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2074Figure  1.  BTLA  expression  is
upregulated in murine peripheral blood
and corneas after HSV-1 infection. The
expression  of  BTLA  on  CD4+  and
CD8+  T  lymphocytes  in  murine
peripheral  blood  was  determined  by
flow cytometry on day 0, 3, 7, 10, 14,
and  21  after  corneal  inoculation  with
HSV-1  (n=6  at  each  time  point).
Peripheral  blood  mononuclear  cells
(PBMC)  were  stained  simultaneously
for CD3, CD4 or CD8, and BTLA. PE
mouse IgG1 was used as isotype control.
A:  The  percentage  of  CD4+  T  cells
expressing BTLA at the indicated time
point  is  shown  in  the  bar  diagrams.
Statistically significant differences were
observed  on  day  3,  7,  10,  and  14
compared  to  day  0  (*p<0.01).  B:
Representative  three-color  flow
cytometry plot of pre-infection (day 0)
versus day 10 post-infection, gated on
CD4+  T  cells  indicating  BTLA
expression in murine peripheral blood.
C:  The  percentage  of  CD8+  T  cells
expressing BTLA for the indicated time
point is shown in the bar diagrams. No
statistically differences were observed
on day 3, 7, 10, 14 and 21 compared to
day 0 (p>0.05). Corneal tissues (D,E)
were  analyzed  by
immunohistochemistry  to  determine
BTLA  expression.
Immunohistochemical staining with an
antibody against BTLA was performed
to  detect  BTLA  expression.  Sections
incubated without a primary antibody
served as negative controls. All tissue
sections  were  counterstained  with
hematoxylin. Brown staining indicates
BTLA  expression.  D:  Corneal  tissues
derived  from  a  normal  uninfected
mouse.  Faint  BTLA  expression  was
only observed in the corneal epithelium
(arrow). E: Cornea tissue derived from
a mouse 10 days after corneal HSV-1
inoculation.  Increased  BTLA
expression was observed in the corneal
epithelium,  stroma,  endothelium,  and
many inflammatory cells that infiltrated
the  corneal  stroma  (arrows).  Original
magnifications, 400×.
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BTLA expression is upregulated in the murine peripheral
blood and cornea after HSV-1 infection: To confirm whether
BTLA  takes  part  in  the  immunopathogenesis  of  HSK  in
BALB/c mice, we first tested the expression of BTLA in the
cornea and peripheral blood of HSV-1 infected mice. BTLA
expression increased in CD4+ T cells, peaking on day 10 after
infection (Figure 1A). A representative plot gated on CD4+ T
cells demonstrated higher BTLA expression (20.14%) on day
10 after corneal inoculation with HSV-1 compared to day 0
(3.10%,  Figure  1B).  However,  BTLA  expression  did  not
increase in CD8+ T cells after HSV-1 infection (Figure 1C).
Immunohistochemistry results for BTLA expression in
the corneas are shown in Figure 1D. In the normal uninfected
mouse cornea, BTLA expression was only detected in the
corneal epithelium (Figure 1D). However, in corneal tissues
derived from HSV-1 infected mice, BTLA expression was
increased in the corneal epithelium, stroma, and endothelium
(Figure  1E).  In  addition,  the  stroma  of  infected  cornea
contained  many  inflammatory  cells  that  expressed  BTLA
Figure  2.  Restriction  enzyme  digestion  of  recombinant  plasmid
pBTLA. M: DNA marker. 1: pBTLA 2: pcDNA3.1 3: pBTLA/
HindIII 4: pBTLA/XbaI 5: pBTLA/HindIII+XbaI.
(Figure 1E). These results indicate that BTLA takes part in the
immunopathogenesis of HSK in BALB/c mice.
Identification of recombinant plasmid pBTLA: Recombinant
plasmids  were  digested  to  540  bp  and  5,500  bp  DNA
fragments,  which  carried  the  target  genes  BTLA  and
pcDNA3.1 (Figure 2). Analysis of DNA sequencing showed
the amplified BTLA gene was identical with that listed in
Figure 3. Expression level of the recombinant plasmid pBTLA. A:
Indirect immunofluorescence detection of BTLA in HEK293 cells.
HEK293  cells  were  previously  transfected  with  1  μg  of  the
recombinant plasmids pBTLA or the empty vector, pcDNA3.1, in a
12-well plate. Forty-eight hours post-transfection, cells were fixed
with acetone, treated with anti-BTLA monoclonal antibody (mAb),
and stained with FITC conjugated secondary antibody. Green: BTLA
protein-positive  HEK293  cells  transfected  with  pBTLA  in
fluorescence  microscope.  B:  western  blot  result  of  recombinant
plasmid pBTLA. HEK293 cells were transiently transfected with 1
μg of pBTLA. Cells were harvested at 24, 48, 72 h after transfection,
lysed, and the cell extract was resolved on a 12% SDS–PAGE gel.
Protein was transferred to a PVDF membrane (Bio-Rad) using a
semi-dry transfer apparatus. Western blot membranes were scanned
using an Odyssey infrared imaging system (Trans-Blot SD, Bio-
Rad). Lane 1 stands for the pcDNA3.1 transfected cell extracts, lanes
2–4 stand for the pBTLA transfected cell extracts at 24, 48, and 72
h post-transfection.
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2076GenBank.  The  restriction  endonuclease  digestion  and
sequence analyses confirmed successful construction of the
recombinant  expression  plasmid  pcDNA-BTLA  (named
pBTLA).
Expression  level  of  the  recombinant  plasmid  pBTLA:  As
shown  in  Figure  3A,  at  48  h  post-transfection,  the
immunofluorescence  intensity  was  high  in  HEK293  cells
transfected with pBTLA. No fluorescence was observed in the
pcDNA3.1 transfected cells using anti-BTLA protein-specific
mAb.
As shown in Figure 3B, western blotting revealed a band
in  the  pBTLA  transfected  cell  extracts  (lanes  2–4)  at
approximately  20  kDa  size  (our  target  BTLA  protein
19.85 kDa). In the pcDNA3.1 transfected cell extracts (Figure
3B; lane 1), no 19.85 kDa band was found. The results indicate
that the target protein BTLA was expressed successfully.
Treatment with pBTLA decreases ocular disease severity:
Following  infection  of  the  cornea  with  HSV-1,  virus
replicated in the epithelium and damaged this tissue. Repair
occurred rapidly, and virus was no longer recovered in tear
films after 6 days. At this time, inflammatory responses in the
cornea were also not grossly evident. However, beginning at
7 to 8 days after infection, opacities of the cornea became
evident and persisted. Mice that were treated with pcDNA3.1
or PBS progressed to severe inflammation, with nearly 85%
of infected corneas progressing to at least severity score 3. On
day  14  after  infection,  12  of  15  pcDNA3.1  treated  eyes
showed severe corneal opacities, and 10 eyes were considered
as scoring over 3. In all, 13 of 15 PBS treated eyes developed
severe corneal opacities, and 11 eyes showed scores above 3.
In contrast, treatment of mice with pBTLA showed markedly
milder stromal keratitis, with only 7 of 15 pBTLA treated eyes
developing mild corneal opacities, and only one progressing
to severity score 3 (Figure 4A). A comparison of average
severity scores at days 8, 10, and 14 postinfection showed
these to be significantly lower (p<0.01) in the pBTLA treated
than the control groups (Figure 4B). These results indicated
that pBTLA treatment decreases ocular disease severity.
Treatment  with  pBTLA  reduces  CD4+  T  cell  response  to
HSV-1  infection  in  corneas:  At  14  days  postinfection,
histological examination showed that the inflamed corneas of
the pcDNA3.1 or PBS control mice were severely swollen,
heavily infiltrated with inflammatory cells, and had numerous
neovascular tissues in the stroma. In contrast, the corneas of
pBTLA  treated  mice  appeared  to  have  only  mild  stromal
edema and little inflammatory cell infiltration (Figure 5A,B).
Single  cell  suspensions  were  prepared  from  corneas  and
analyzed by flow cytometry for CD4+ T cells numbers. As
shown in Figure 5C-E, the absolute number and percentage of
CD4+  T  cells  from  cornea  of  pBTLA  treated  mice  were
significantly lower than those of pcDNA3.1 or PBS control
mice (p<0.01). These results indicated that treatment with
pBTLA dramatically reduced the CD4+ T cell response to
HSV-1 infection in the cornea.
The  pBTLA  treated  mice  showed  a  lower  Th1  immune
response: In an attempt to explain why pBTLA treated mice
showed slighter responses than those of pcDNA3.1 or PBS
treated mice, we examined the number of CD4+ IFN-γ+ T cells
in the corneas of different group mice on day 14 postinfection.
Significantly fewer CD4+ IFN-γ+ T cells (p<0.01) were found
in the cornea of pBTLA treated mice when compared with
control groups (Figure 6A,B). Flow cytometry measurement
also revealed fewer IFN-γ+ T cells in the draining lymph nodes
(DLNs) of pBTLA treated mice (p<0.01) than in the control
groups (Figure 6C,D). Splenocytes from pBTLA treated mice
also produced significantly lower (p<0.01) amounts of IFN-
Figure  4.  Treatment  with  pBTLA
decreases the clinical severity of HSK.
HSK lesion severity was determined by
slit-lamp  biomicroscopy,  and  the
clinical severity of stromal keratitis of
individually scored mice was recorded.
Stromal keratitis was graded from 0 to
4+, depending on the corneal opacity
with  neovascularization,  edema,  and
infiltration.  Each  group  of  mice
consisted  of  fifteen  animals,  and  the
results shown are the representative of
two similar experiments. A. Each dot
represents  corneal  opacity  of  an
individual  BALB/c  eye  on  day  14
following  HSV-1  infection.  Crossbar
indicates  the  mean.  *p<0.01  versus
control groups. B. HSK lesion scores in
three groups of mice at different time
points  post  infection.  *p<0.01  versus
control groups.
Molecular Vision 2010; 16:2071-2083 <http://www.molvis.org/molvis/v16/a223> © 2010 Molecular Vision
2077γ as compared to pcDNA3.1 or PBS treated mice (Figure 6E).
Thus, pBTLA treatment appeared to decrease the Th1 type of
immune response of mice.
Treatment  with  pBTLA  suppresses  the  systemic  DTH
responses of mice: The DTH responses of the footpad in the
different  mice  groups  two  weeks  after  viral  infection  are
shown in Figure 7. The DTH responses in all infected groups
were significantly higher than uninfected controls (p<0.01).
In addition, DTH responses in pBTLA treated mice were
lower than in pcDNA3.1 or PBS treated mice (p<0.01). The
results  indicated  that  pBTLA  treatment  inhibited  immune
cell-mediated inflammation induced by HSV-1.
Treatment with pBTLA does not affect virus titers in tear film:
Tear film virus titers on days 1, 3, and 5 following HSV-1
infection  are  shown  in  Figure  8.  Mice  systemically
administered pBTLA showed no difference in virus titer from
pcDNA3.1 treated or PBS control mice (p>0.05). Systemic
administration  of  recombinant  pBTLA  therefore  did  not
appear to affect virus titers in tear film.
Figure 5. Decreased inflammation in the corneas of mice treated with pBTLA. A: pBTLA treated, pcDNA3.1 treated and PBS control mice
were infected with 1×105 PFU of HSV-1 KOS. On day 14 postinfection, mice were euthanized, and eyes were processed for cryosectioning.
H&E staining was conducted on 5-µm sections. The corneas in the pcDNA3.1 treated and PBS control groups show severe swelling, heavy
infiltration with inflammatory cells, and numerous neovascular structures in the stroma. The cornea in the pBTLA treated group exhibits only
mild stromal edema, little inflammatory cell infiltration, and fewer neovascular structures. Original magnification, 400×. B: Six corneal
samples from each group of animals were digested with liberase on day 14 post infection. The bars represent the total number of viable cells
present per cornea of different groups of mice. *p<0.01 compared with control groups. C: The cells isolated from infected corneas were stained
for CD4 marker and the bars represent the total number of CD4+ T cells present per cornea from different groups of mice. Decreased numbers
of CD4+ T cells in the cornea of pBTLA treated mice. *p<0.01 compared with control groups. D: The percentage of CD4+ T cells in total cells
of per cornea from different groups of mice. *p<0.01 compared with control groups. E: Representative plot shows CD4+ T cells expression
on cornea of different group mice.
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2078Treatment  with  pBTLA  does  not  affect  gD  expression  in
cornea: The gD mRNA levels in corneas from mice treated
intraperitoneally with pBTLA and in, pcDNA3.1 treated mice
and PBS control mice at 72 h after HSV-1 infection are shown
in Figure 9. No differences were seen in levels of gD mRNA
expression in the corneas of pBTLA treated mice compared
to  the  control  mice  (p>0.05).  These  data  indicated  that
systemic administration of recombinant pBTLA did not affect
gD expression in the mouse cornea.
Figure 6. pBTLA treated mice show a lower Th1 immune response. A: On day 14 after HSV-1 infection, single-cell suspensions of cornea
cells were prepared from mice from different groups. Cells were stained by anti-CD3e-FITC, anti-CD4-APC, PE anti-mouse IFN-γ- or PE
Rat IgG1 Isotype control as described in Methods. Dot plots represent the frequencies of CD4+ IFN-γ+ T cells from pBTLA treated mice,
pcDNA3.1 treated mice, and PBS control mice when gated on the lymphocytes. The percentage of CD4+ T cells expressing IFN-γ is shown
in the upper right quadrants. B: The bar diagram demonstrates the total number of CD4+ IFN-γ+ T cells in the cornea in different groups (n=6
in each group). Decreased numbers of CD4+ INF-γ+ T cells are noted in the corneas of pBTLA treated mice (*p<0.01 compared with control
groups). C: On day 14 after HSV-1 infection, single-cell suspensions of cervical draining lymph nodes were prepared from mice from different
groups. Cells were stained by anti-CD3e-FITC, anti-CD4-APC, PE anti-mouse IFN-γ-, or PE Rat IgG1 Isotype control. Dot plots represent
the frequencies of IFN-γ+ T cells from different group mice. The number of IFN-γ+ T cells and the percentage of IFN-γ+ T cells in all T cells
are shown in the right quadrants. D: The bar diagram demonstrates the total number of IFN-γ+ T cells in the DLNs in different groups (n=6
in each group). Fewer numbers of IFN-γ+ T cells in the DLN of pBTLA treated mice (*p<0.01 compared with control groups). E: On day 14
after HSV-1 infection, spleen cells of the mice from different groups (n=6 in each group) were used in antigen specific ELISA. Levels of IFN-
γ in pBTLA treated mice were lower than in pcDNA3.1 or PBS treated mice (*p<0.01).
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2079DISCUSSION
Herpes simplex virus type 1 infection of the mouse cornea
leads  to  a  transient  epithelial  lesion  caused  by  HSV-1
replicating in and destroying corneal epithelial cells. This
lesion  is  evident  by  2  days  after  infection.  Repair  occurs
rapidly,  and  virus  characteristically  can  no  longer  be
recovered in tear film after 5 to 6 days, at which time virus
replication in the cornea has usually ceased. This means that
after this time, the virus is thought to be expelled from corneal
tissues by one or more aspects of host defense. However, T-
cell invasion of the cornea begins 7 days after infection, a mild
haze develops in the infected mouse cornea stroma, and limbal
blood vessels begin to invade this normally avascular tissue.
This  represents  the  initiation  of  the  chronic  phase  of  the
disease. The inflammation is progressive, leading to severe
neovascularization and opacity, referred to as HSK [4].
Therapeutic targets in HSK include the HSV virus itself
and the key host processes involved in the pathogenesis (the
inflammatory immune response and angiogenesis). Treatment
of  HSK  traditionally  involves  antiviral  drugs  and  anti-
inflammatory drugs such as corticosteroids. Development of
an effective vaccine against HSV has proven to be elusive so
far [4]. New information about immunological mechanisms
would therefore provide novel avenues for the improvement
of HSK therapy. The pathogenesis of HSK, as studied in the
mouse, involves numerous components, but CD4+ T cells
Figure 7. pBTLA plasmid treatment suppresses the systemic DTH
responses of mice. pBTLA and pcDNA3.1 treated mice received 100
µg of the respective plasmid on days −7, 0, 7 relative to HSV-1
corneal inoculation, PBS treated mice received 100 µl PBS i.p. Two
weeks after viral infection, DTH responses were measured in the
footpad. All infected groups (n=6 in each group) had significant
responses compared with the uninfected control mice (*p<0.01).
DTH  responses  in  pBTLA  treated  mice  were  lower  than  in
pcDNA3.1 or PBS control mice (#p<0.01).
appear  to  be  the  principal  orchestrators  of  the
immunopathology [1-7,25,26].
The response of immune cells, particularly T cells and
antigen-presenting cells (APCs), is dictated by the balance
between negative signals from co-inhibitory receptors and
positive signals from costimulatory receptors. Since CD4+ T
cells are the primary effectors of stromal lesions of HSK,
targeting costimulatory and coinhibitory signals of CD4+ T
cell activation and decreasing the numbers of CD4+ T cells
would be a useful therapeutic approach [8-10,27]. The best-
characterized  costimulatory  signals  determined  to  be
important in the initiation of the immune response are the B7/
CD28 and CD40/CD154 receptor-ligand interactions. Several
groups  have  studied  the  roles  of  these  two  costimulatory
signals  in  viral  pathogenesis  by  exploring  the  effects  of
blocking  costimulatory  signals  in  the  well  characterized
lymphocytic choriomeningitis virus (LCMV) and vesicular
stomatitis virus (VSV) models in mice. Antiviral CD4+ T-cell
responses to both viruses are moderately dependent on these
costimulatory signals [28].
The B7/CD28 and CD40/CD154 costimulatory signals
have  also  been  successfully  targeted  for  therapeutic
intervention  in  primary  HSV  infection  [8,9,29].  Systemic
blockade of B7/CD28 costimulatory interactions using fusion
protein  CTLA4Ig  minimizes  the  immunoinflammatory
lesions  caused  by  HSV  infection  of  the  cornea  [8,9].
Figure 8. pBTLA treatment does not affect virus titers in tear film.
Tear film virus titers were compared in the different mice groups
following  HSV-1  infection.  Mice  treated  with  pBTLA  and
pcDNA3.1 received 100 μg of the respective plasmid on days, −7, 0,
7 relative to HSV-1 corneal inoculation, and the PBS group received
100 µl PBS intraperitoneally. On days 1, 3, and 5, swabs of the
corneal surface were collected and transferred to serum-free DMEM,
and viral titers were determined by a plaque assay performed on
VERO cells as described in methods. The virus titers was calculated
as log10PFU/ml. Results are expressed as means±SD for individual
eye  swabs  (n=6).  No  statistically  significant  differences  were
observed among the different groups (p>0.05).
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2080Disruption of B7/CD28 and CD40/CD154 interactions with
blocking  reagents  (CTLA4Ig  and  MRI)  or  in  mice  with
genetic  deficits  in  either  CD28  or  CD154,  profoundly
impaired CD4+ T-cell responses during primary acute HSV-1
infection  of  the  hind  footpads  [29].  Another  candidate-
inducible costimulatory pair that has been targeted for the
alleviation  of  HSK  is  the  4–1BB/4–1BBL  costimulatory
signal  [10].  Inhibition  of  the  inducible  4–1BB/4–1BBL
costimulatory pathway by administration of anti-mouse 4–
1BBL mAb systemically inhibited CD4+ T-cell infiltration
into infected corneas, resulting in reduced HSK [10].
BTLA, an inhibitory coreceptor that negatively regulates
lymphocyte activation, plays a critical role in several immune-
inflammatory  diseases  [18-20,30].  To  determine  whether
BTLA  takes  part  in  the  immunopathogenesis  of  HSK  in
BALB/c mice, we first tested the level of BTLA expression
on CD4+ and CD8+ T cells in murine peripheral blood by flow
cytometry during HSK. At the same time, we also confirmed
BTLA  expression  in  the  murine  cornea  by
immunohistochemistry.  We  found  that  BTLA  expression
increased both in the cornea of HSV-1 infected mice and in
CD4+ T cells in the peripheral blood, indicating that BTLA
does participate in the immune response that occurs in HSK.
The next issue was to investigate the role of BTLA during
HSK.  In  this  study,  we  investigated  whether  systemic
administration of recombinant plasmid DNA encoding BTLA
(pBTLA) could decrease the numbers of CD4+ T cells that
infiltrated into infected corneas, resulting in reduced HSK.
BALB/c mice that received an intraperitoneal administration
of 100 µg of pBTLA on 0 and 7 days before infection and 7
days  postinfection  showed  a  diminished  incidence  and
severity  of  the  stromal  disease.  The  absolute  amount  and
percentage of CD4+ T cells from cornea of pBTLA treated
mice were significantly lower than those of pcDNA3.1 treated
mice or PBS control mice. The results indicated that systemic
administration of pBTLA dramatically reduced CD4+ T cell
response to HSV-1 infection in cornea. This could mean that
BTLA-HVEM coinhibitory signaling may play a crucial role
in  preventing  HSV-induced  corneal  immunopathology
mediated by CD4+ T cells.
The  role  of  pBTLA  in  CD4+  Th1  immune  responses
during  HSK  was  further  investigated  by  examining  the
number of CD4+ T cells expressing IFN-γ+ in the corneas of
different group mice on day 14 after in vivo HSV-1 infection.
The result shows that CD4+ T cells expressing IFN-γ+ in the
cornea of pBTLA treated mice were fewer when compared
with control groups. Flow cytometry measurement of IFN-γ
+ T cells in the DLN from different group mice revealed
similar results. We also collected splenocytes of different
mice groups and tested HSV specific Th1 cell responses. The
IFN-γ concentrations were reduced in splenocytes isolated
from pBTLA treated mice when stimulated in vitro, indicating
that  pBTLA  treated  mice  had  a  reduced  Th1  immune
response. This was also supported by our results for DTH
responses in the mice.
The DTH response is an immune response that occurs
when antigen activated Th1 cells release pro-inflammatory
cytokines at the site of antigen recognition. In the eye, the
cytokines,  cellular  infiltration,  and  vascular  changes  that
accompany DTH responses are an immediate and long-term
detriment to corneal clarity. In ocular HSV-1 infection, a
reduction in the severity of HSK has been shown in DTH
tolerant mice, while elevated DTH responses are associated
with greater corneal pathology in HSK [23,31,32]. In the
Figure 9. Effect of recombinant pBTLA
on the levels of gD mRNA expression in
cornea.  Real-time  quantitative  PCR
analysis of gD mRNA levels results are
shown  for  corneas  from  the  different
mouse groups (n=6 in each group) at 72
h  after  HSV-1  infection.  RNA  was
extracted from corneas of mice from the
different groups and the levels of gD
expression were evaluated through real-
time  quantitative  PCR.  A:  The  melt
curves  of  gD  and  GAPDH  after
amplification in corneal samples. B: The
fold changes of gD mRNA expression
in corneas of different groups at 72 h
postinfection. The gD mRNA levels in
the corneas of pBTLA treated mice did
not differ from those of the pcDNA or
PBS control mice (p>0.05).
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2081present study, pBTLA treated mice showed a reduced DTH
response  two  weeks  after  HSV-1  infection  compared  to
pcDNA  or  PBS  treated  mice.  Systemic  administration  of
recombinant pBTLA decreased the role of characteristic Th1
cytokines during HSV-1 infection.
The entry of HSV-1 into cells is well known to require
membrane  fusion  between  the  virus  envelope  and  cell
membrane, which is primarily mediated by the interaction of
the viral ligand, glycoprotein D(gD)and its cellular receptor
HVEM [33-35]. HSV has evolved the ability to enter and
infect  T  cells.  Activation  of  T  cells  increased  their
permissivity toward HSV infection. HSV infection of both
CD4+ and CD8+ T cells occurred much more efficiently via
direct cell-to-cell spread from infected fibroblasts than by
cell-free virus. Transfer of HSV to T cells depends mainly on
the binding of gD to its receptor, HVEM [36]. gD is expressed
on the surface of activated T cells after infection [37]. The
membrane-bound gD can exert an immunomodulatory effect
on activated T cells [35,37-39]. Comparison of the gD and
BTLA binding sites on HVEM shows that the BTLA and gD
binding  sites  are  largely  overlapping  and  involve  similar
structural  motifs  as  well  as  similar  energetics  [12,40].
However, in this report we demonstrate that intraperitoneal
application of recombinant pBTLA did not affect gD-mRNA
levels or tear film virus titers in corneas. Further study will be
done on the corneal treatment with pBTLA to test whether
intraocular administration can affect corneal viral titer and gD
levels.
In summary, the present study provides evidence that the
BTLA-HVEM coinhibitory signal is functionally involved in
the  HSV-induced  corneal  immunopathology  mediated  by
CD4+ T cells. Promoting the BTLA-HVEM interaction by
recombinant pBTLA may represent an ideal target for HSK
therapy to suppress the immune reaction and avoid corneal
scarring.
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